Premium
The number of circulating CD26 expressing cells is decreased in critical COVID ‐19 illness
Author(s) -
deKay Joanne T.,
May Teresa L.,
Riker Richard R.,
Rud Jonathan,
Gag David J.,
Sawyer Douglas B.,
Seder David B.,
Ryzhov Sergey
Publication year - 2023
Publication title -
cytometry part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.316
H-Index - 90
eISSN - 1552-4930
pISSN - 1552-4922
DOI - 10.1002/cyto.a.24547
Subject(s) - covid-19 , cd3 , immunology , t cell , medicine , peripheral blood , disease , immune system , cd8 , infectious disease (medical specialty)
We evaluated the number of CD26 expressing cells in peripheral blood of patients with COVID‐19 within 72 h of admission and on day 4 and day 7 after enrollment. The majority of CD26 expressing cells were presented by CD3 + CD4 + lymphocytes. A low number of CD26 expressing cells were found to be associated with critical‐severity COVID‐19 disease. Conversely, increasing numbers of CD26 expressing T cells over the first week of standard treatment was associated with good outcomes. Clinically, the number of circulating CD26 cells might be a marker of recovery or the therapeutic efficacy of anti‐COVID‐19 treatment. New therapies aimed at preserving and increasing the level of CD26 expressing T cells may prove useful in the treatment of COVID‐19 disease.